Guardant blood test shows promise in predicting immunotherapy response; AstraZeneca's diabetes drug wins EU label expansion - Endpoints News

Guardant blood test shows promise in predicting immunotherapy response; AstraZeneca's diabetes drug wins EU label expansion  Endpoints News

Prisoner #87850-053 does not get to add drug developer to his list of credits. Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases